Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | TACR3 | P29371 | 10/20 | 0.44 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917791 | 1.00 | CYP2C9 (0.47) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL16566393 | 1.00 | CYP2C9 (0.47) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL11917787 | 1.00 | CYP2C9 (0.47) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL11917794 | 1.00 | CYP2C9 (0.47) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL7948901 | 0.97 | CYP2C9 (0.50) | CYP2C9TACR3PDE2APPARG | |
| SCHEMBL11917792 | 0.94 | CYP2C9 (0.46) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL11917795 | 0.94 | CYP2C9 (0.46) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL11917788 | 0.94 | CYP2C9 (0.46) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL7950413 | 0.94 | CYP2C9 (0.46) | CYP2C9TACR3PDE2AOPRL1MEN1 | |
| SCHEMBL2149783 | 0.92 | CYP2C9 (0.46) | CYP2C9TACR3PDE2AOPRL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041509-B1 | NKR3 ANTAGONISTS FOR TREATING OR PREVENTING HOT FLUSHES | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| US-20160220555-A1 | Method For Treating Or Preventing Hot Flushes | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220555-A1 | Method For Treating Or Preventing Hot Flushes | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-2342182-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-11-14 | — | — | EP | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028655-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | CYP2C9 3674/4885TACR3 34/4885PDE2A 884/4885 |
| US-20160220555-A1 | Method For Treating Or Preventing Hot Flushes | KLK5, KISS1R, KLKB1 | CYP2C9 1869/4885TACR3 7/4885PDE2A 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.